Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission

Neuropharmacology

Volumn 53, Issue 3, 2007, Pages 379-389

  Wang, Dayong ^a,b,f   Noda, Yukihiro ^a,c   Zhou, Yuan ^a   Nitta, Atsumi ^a   Furukawa, Hiroshi ^d   Nabeshima, Toshitaka ^a,d,e  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Japanese Society of Pharmacopoeia   (Japan)

^c Faculty of Pharmacy   (Japan)

^d MEIJO UNIVERSITY   (Japan)

^e Japanese Drug Organization of Appropriate Use and Research   (Japan)

^f UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cognitive impairment; Dopamine; Galantamine; nAChR; Phencyclidine; Risperidone; Schizophrenia; Synergistic effect

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; GALANTAMINE; MECAMYLAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RISPERIDONE; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG POTENTIATION; LEARNING; LOW DRUG DOSE; MALE; MEMORY; MENTAL DISEASE; MICRODIALYSIS; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; REPEATED DRUG DOSE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; GALANTAMINE; LEARNING DISORDERS; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; MICRODIALYSIS; NOOTROPIC AGENTS; PHENCYCLIDINE; REACTION TIME; RECEPTORS, DOPAMINE D1; RECEPTORS, NICOTINIC; RISPERIDONE; SPACE PERCEPTION;

EID: 34547657189     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.05.026     Document Type: Article

References (65)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 7 Suppl. 1 (2004) S1-S5
2. Albert K.A., Hemmings H.C., Adamo A.I.B., Potkin S.G., Akbarian S., Sandman C.A., Cotman C.W., Bunney W.E., and Greengard P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch. Gen. Psychiatry 59 (2002) 705-712
3. Arnold D.S., Rosse R.B., Dickinson D., Benham R., Deutsch S.I., and Nelson M.W. Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient. J. Clin. Psychiatry 65 (2004) 1723-1724
4. Balla A., Koneru R., Smiley J., Sershen H., and Javitt D.C. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 25 (2001) 157-164
5. Bickel U., Thomsen T., Fischer J.P., Weber W., and Kewitz H. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30 (1991) 447-454
6. Bickel U., Thomsen T., and Weber W. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin. Pharmacol. Ther. 50 (1991) 420-428
7. Bilder R., Goldman R., and Robinson D. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157 (2000) 549-559
8. Bischoff S., Heinrich M., Sonntag J.M., and Krauss J. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT 2) receptors. Eur. J. Pharmacol. 129 (1986) 367-370
9. Bischoff S., Heinrich M., Krauss J., Sills M.A., Williams M., and Vassout A. Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome. J. Recept. Res. 8 (1988) 107-120
10. Bora E., Veznedaroglu B., and Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin. Neuropharmacol. 28 (2005) 139-141
11. Brewer W., Francey S., and Wood S. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry 162 (2005) 71-78
12. Cao Y.J., Surowy C.S., and Puttfarcken P.S. Nicotinic acetylcholine receptor mediated dopamine release from hippocampus. J. Pharmacol. Exp. Ther. 312 (2005) 1298-1304
13. Castner S.A., Goldman-Rakic P.S., and William G.V. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 174 (2004) 111-125
14. Christensen A.V., Arnt J., Hyttel J., and Svendsen O. Behavioural correlates to the dopamine D-1 and D-2 antagonists. Pol. J. Pharmacol. Pharm 36 (1984) 249
15. Daniel M.P., Mores C., Carite L., Boyer P., and Denis M. Dysfunction of spatial cognition: the case of schizophrenic patients. Cogn. Process 7 Suppl. 1 (2006) S173
16. Deutsch S.I., Rosse R.B., Schwartz B.L., Weizman A., Chilton M., Arnold D.S., and Mastropaolo J. Therapeutic implications of a selective α7 nicotinic receptor abnormality in schizophrenia. Isr. J. Psychiatry Relat. Sci. 42 (2005) 33-44
17. Farlow M.R. Clinical pharmacokinetics of galantamine. Clin. Pharmacokinet 42 (2003) 1383-1392
18. Fink-Jensen A. Novel pharmacological approaches to the treatment of schizophrenia. Dan. Med. Bull. 47 3 (2000) 151-167
19. Franklin J.B.J., and Paxinos G.T. The Mouse Brain: in Stereotaxic Coordinates (1997), Academic Press, New York
20. Friedman J.I. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 174 (2004) 45-53
21. Gabrovska V., Laws K., and McKenna P.J. Visual object perception in schizophrenia: further evidence for a selective impairment in semantic memory. Schizophr. Res. 24 (1997) 103
22. Geerts H., Guillaumat P.O., Grantham C., Bode W., Anciaux K., and Sachak S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice and rabbits. Brain Res. 1033 (2005) 186-193
23. Gillett R. Object relocation task: an exact test of significance with credit for partial knowledge. Br. J. Math. Stat. Psychol 55 Pt 2 (2002) 199-211
24. Glahn D.C., Gur R.C., Ragland J.D., Cannon T., and Gur R. An examination of visual learning in patients with schizophrenia: evidence of a deficit in acquisition of novel information. Schizophr. Res. 24 (1997) 103
25. Goudie A.J., Smith J.A., and Millan M.J. Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine. Psychopharmacology 171 (2004) 212-222
26. Greenslade R.G., and Mitchell S.N. Selective action of (-)-2-oxa-4-aminobicyclo [3.1.0] hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology 47 (2004) 1-8
27. Huang F., Lasseter C., Janssens L., Verhaeghe T., Lau H., and Zhao Q. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J. Clin. Pharmacol. 42 (2002) 1341-1351
28. Ichihara K., Nabeshima T., and Kameyama T. Dopaminergic agonists impair latent learning in mice: possible modulation by noradrenergic function. J. Pharmacol. Exp. Ther. 264 (1993) 122-128
29. Ichikawa J., Dai J., O'Laughlin L.A., Fowler W.L., and Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26 (2002) 325-339
30. Iorio L.C., Barnett A., Leitz F.H., Houser V.P., and Korduba C.A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 226 (1983) 462-468
31. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
32. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
33. Jentsch J.D., Dazzi L., and Roth R.H. Subchronic phencyclidine exposure reduces basal dopamine efflux and augments the cholinergic and catecholaminergic response to clozapine. Soc. Neurosci. Abstr. 24 (1998) 744
34. Jentsch J.D., Taylor J.R., and Roth R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19 (1998) 105-113
35. Khan B.U. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. J. Autism Dev. Disord 27 (1997) 479-489
36. Kolb B. Prefrontal cortex. In: Kolb B., and Tees R.C. (Eds). The Cerebral Cortex of the Rat (1990), MIT Press, Cambridge, MA 437-458
37. Kumari V., and Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci. Biobehav. Rev. 29 (2005) 1021-1034
38. Lee S.W., Lee J.G., Lee B.J., and Kim Y.H. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int. Clin. Psychopharmacol. 22 (2007) 63-68
39. Loas G. Visual-spatial processing and dimensions of schizophrenia: a preliminary study on 62 schizophrenic subjects. Eur. Psychiatry 19 (2004) 370-373
40. Mackintosh N.J. A theory of attention: variations in the associability of stimuli with reinforcement. Psychol. Rev. 82 (1975) 276-298
41. Maddox V.H., Godefroi E.F., and Parcell R.F. The synthesis of phencyclidine and other 1-arylcyclohexylamines. J. Med. Chem. 56 (1965) 230-235
42. Maruff P., Malone V., and Currie J. Asymmetries in the covert orienting of visual spatial attention to spatial and non-spatial cues in Alzheimer's disease. Brain 118 Pt 6 (1995) 1421-1435
43. McGhie A., and Chapman. Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 34 (1961) 103-116
44. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modeling schizophrenia. Curr. Opin. Pharmacol. 5 (2005) 101-106
45. 2 receptors. Neurosci. Lett. 102 (1989) 303-308
46. Nagai T., Yamada K., Yoshimura M., Ishikawa K., Miyamoto Y., Hashimoto K., Noda Y., Nitta A., and Nabeshima T. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc. Nat. Acad. Sci. U.S.A. 101 (2004) 3650-3655
47. Noda Y., Yamada K., Furukawa H., and Nabeshima T. Enhancement of immobility in a forced swimming test by subacute of repeated treatment with phencyclidine: a new model of schizophrenia. Br. J. Pharmacol. 116 (1995) 2531-2537
48. Noda Y., Kamei H., Mamiya T., Furukawa H., and Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23 (2000) 375-387
49. Noda A., Noda Y., Kamei H., Ichihara K., Mamiya T., Nagai T., Sugiura S., Furukawa H., and Nabeshima T. Pencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma1 receptors. Neuropsychopharmacology 24 (2001) 451-460
50. Rabenstein R.L., Caldarone B.J., and Picciotto M.R. The nicotinic antagonist mecamylamine has antidepressantlike effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology 189 (2006) 395-401
51. Salminen O., Murphy K.L., Mclntosh J.M., drago J., Marks M.J., Collins A.C., and Grady S.R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 65 (2004) 1526-1535
52. Samochocki M., Hoffle A., Fehrenbacher A., Jostock R., Ludwig J., Christner C., Radina M., Zerlin M., Ullmer C., Pereira E.F., Lubbert H., Albuquerque E.X., and Maelicke A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 305 (2003) 1024-1036
53. Scott L.J., and Goa K.L. Galantamine: a review of its use in Alzheimer's disease. Drugs 60 (2000) 1095-1122
54. Sharp B.M., Yatsula M., and Fu Y. Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J. Pharmacol. Exp. Ther. 309 (2004) 1116-1123
55. Shayegan D.K., and Stahl S.M. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 9 10 Suppl. 11 (2004) 6-14
56. Shintani F., Kanba S., Nakaki T., Nibuya M., Kinoshita N., Suzuki E., Yagi G., Kato R., and Asai M. Interleukin-1b augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J. Neurosci. 13 (1993) 3574-3581
57. Thomsen T., Kaden B., and Fischer J.P. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur. J. Clin. Chem. Clin. Biochem. 29 (1991) 487-492
58. Van't Wout M., Kessels R.P., and Kahn R.S. Object-location memory in schizophrenia: interference of symbolic threatening content. Cognit. Neuropsychiatry 11 (2006) 272-284
59. Venables P.H. The effect of auditory and visual stimulation on the skin potential responses of schizophrenics. Brain 83 (1960) 77-92
60. 25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32 (2007) 1261-1271
61. Wang D., Noda Y., Zhou Y., Nitta A., Furukawa H., and Nabeshima T. Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model. Neuropharmacology 52 (2007) 1179-1187
62. 2 receptor selectivities of phenyl-benzazepines in rhesus monkey striata. Eur. J. Pharmacol. 361 (1998) 129-142
63. Wonnacott S. Presynaptic nicotinic Ach receptors. Trends Neurosci. 20 (1997) 92-98
64. Xiao Y., and Kellar K.J. The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells. J. Pharmacol. Exp. Ther. 310 (2004) 98-107
65. Zhang L., Zhou F.M., and Dani J.A. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol. 66 (2004) 538-544